21 October 2013
This year's crop endured the struggles many startups face and came out ahead. They've attracted substantial funding from major investors in a tough market, proving the worth of their products. Many are also already in--or close to--market with their signature products, a sign of stability that draws investor commitments much more these days than companies on the earlier side of development.
26 September 2013
The inlay creates multifocality at the corneal plane, with near vision on the visual axis and a transition to intermediate, distance vision out to the periphery.
05 September 2013
Syndax Pharmaceuticals Inc., which is developing epigenetic therapies for treatment-resistant cancers and Eddingpharm, a leading specialty pharmaceutical company in China, entered into a licensing, development and commercialization agreement that gives Eddingpharm exclusive rights to develop, market and sell entinostat in China and certain other Asian countries/regions.
30 June 2013
Corneal inlays are designed to treat presbyopia by being inserted in the non-dominant eye and correcting for near vision; distance vision remains (mostly) unaffected.
04 February 2013
Nanotechology, which involves controlling matter at the molecular and atomic levels, was a much-hyped investment theme a decade ago. It’s since become widely used in commercial products ranging from solar panels to semiconductors, but investing in nanotech requires patience.
01 February 2013
Tracey Sunderland, COO, Coda Therapeutics Inc: “We think we’ve got something that has the potential to be a real game changer in this space particularly due to the fact that there are no therapeutic compounds on the market currently.”
09 January 2013
CoDa Therapeutics, Inc. today announced positive results from a Phase 2b clinical trial of NEXAGON® in patients with chronic venous leg ulcers. NEXAGON® is an easy to administer, once-a-week, topical, drug candidate being developed for the treatment of chronic wounds. It is designed to increase the incidence of wound healing compared to existing therapeutic techniques, and to heal them much faster. The company believes these results support advancing NEXAGON into Phase 3 registration trials. Venous leg ulcers are increasingly common and costly, and can be a cause of prolonged suffering for patients.
07 January 2013
Marinus Pharmaceuticals, Inc. is pleased to announce $21 million in new Series C financing from U.S. venture capital firm Domain Associates, LLC, Rusnano subsidiary RusnanoMedInvest (RMI), and co-investors.
24 July 2012
CoDa Therapeutics, Inc. announced today that it raised an additional NZ$24.5M from Russian investment firm RusnanoMedInvest (“RMI”). This brings the company’s total Series B Round to nearly NZ$49 million following a first close late last year.
06 October 2011
Square 1 Bank, the exclusive banking partner to entrepreneurs and the venture capital community, is pleased to partner with CoDa Therapeutics, Inc. in providing a $6 million term loan.
24 May 2019
23 May 2019
22 May 2019
22 May 2019